• About
    • Mission
    • Meet Brian
    • Meet the Kelleys
    • Brian’s Artwork
    • Photo Gallery
  • ALD
    • What is ALD?
    • Diagnosis & Treatment
    • Newborn Screening FAQs
    • Support Newborn Screening
    • Educational Videos
    • Additional Resources
  • Events
    • Hammerfest Triathlon
    • Lions Golf
    • Hook & Slice
  • Take Action
    • Volunteer/Sponsor
    • Donate
  • News
  • Contact

FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy

May 24, 2018 by Brian's Hope

FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy

We have incredible news to share! Massachusetts-based bluebird bio, a leader in the research and treatment of cancer and severe genetic diseases, just received FDA “Breakthrough Therapy” designation for their Lenti-D™ gene therapy for patients with cerebral adrenoleukodystrophy (CALD).

This designation will allow for expedited development and review of the treatment protocol, meaning it is well on its way to becoming a mainstream treatment option! We are thrilled at the progress bluebird has already made, and the positive results from the treatment study that led to this designation.

Read more about this potentially life-changing news, and join us in celebrating a major step in the treatment of ALD! Thank you, bluebird bio!

Filed Under: In the News...

Updates

Latest News on ALD

Recent Posts

  • FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy May 24, 2018
  • California Begins Newborn Screening for ALD October 3, 2016
  • 20th Annual Hammerfest was an Amazing Success October 3, 2016
  • Press Conference on ALD Newborn Screening Success Held in Connecticut September 2, 2016

Sort By Topic:

Sort by Date:

Newborn Screening
Status Nationwide

ALD
Awareness

Read the
Latest News

Brian’s Hope is a 501(c)(3) Charitable Foundation

Built by the team at Acara Partners